oncgnostics presents extended version of its cervical cancer diagnostics test GynTect at MEDICA
Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of cervical cancer – at the world-leading trade fair Medica. Between 14th and 17th of November 2016 the epigenetics experts will explain the advantages of the test compared to the methods currently available in cervical cancer early detection as well as the new features of the extended GynTect version. The company will also provide information at its booth concerning the current status of its pipeline projects in ovarian as well as head-and-neck cancer diagnostics.
After its successful regulatory approval with CE IVD mark in autumn 2015 oncgnostics continuously refined its cervical cancer triage test GynTect. This new version allows for a much broader range of applications in gynecologic practices and laboratories. GynTect may now be performed directly from a widely used cervical smear medium (PreservCyt, Hologic). This medium allows for both, an advanced form of the microscopic cervical smear examination, the so-called ThinPrep cytology (a version of the Pap test), as well as for HPV tests using the methods developed by different companies. For the first GynTect version a separate cervical smear was required, whereas the new test may now be performed using an already available thin-layer cytology sample. Thus, GynTect also corresponds to the provisions of new guidelines which claim that triage tests in cervical cancer diagnostics need to be performed from the same sample as the initial screening test.
With GynTect oncgnostics has developed a molecular diagnostic test which clarifies early and reliably if a patient with abnormal Pap smear and/or a high-risk HPV infection has a cervical precancerous lesion or cancer that requires treatment. The diagnostic procedure is based on the detection of epigenetic changes in cells of a cervical smear. The emergence of specific epigenetic markers indicates that a precancerous lesion or a carcinoma may be present. Thus, GynTect provides secure test results, which improve the risk assessment in cervical cancer screening: on one hand, unnecessary and hasty surgeries may be avoided; on the other hand true signs of cervical cancer and its preliminary stages may be identified timely. This improves the prospects for early and successful therapeutic measures drastically.
With a team of experts oncgnostics exhibits at the Medica from 14th to 17th of November 2016 at booth E21 in hall 15, a joint stand organized by medways e.V., Jena. On this occasion, the new GynTect will be presented to a large professional audience for the first time. Expert contacts on site are the two managing directors, Dr. Martina Schmitz and Dr. Alfred Hansel. Upon interest in a press interview, please contact us in advance using pr@oncgnostics.com
Medica is THE leading international trade fair and congress for medical technology, electrical medicine, lab equipment, diagnostics and medicines. Ca. 4800 exhibitors from more than 70 countries utilize the Medica as the leading fair for presenting new products and services.
GynTect® is a registered trademark owned by oncgnostics GmbH.
Links:
Find cost-free picture material concerning this press release, the test and the company here:http://www.epitype.de/downloads
